ABL Bio-Technologies Limited
Add to watch list to get report alerts
BSE Code:
526955
NSE Code:
Business Profile
Business Profile
ABL Biotechnologies (ABLBIO) is engaged in the identification and commercial extraction of biochemicals. It was incorporated as a private limited company in March 1992 and converted into a public limited company in March 1994.
The company operates through its three divisions of Spectrum, Invia Health and Sanctum Nutrition. It engages in research and development activities covering the areas of bioresources focusing on living organisms; chemistry, working on the strategic areas of synthesis and bioprocess development; clinical biology area focusing on nine different disease states; and special projects working developing platform technologies in molecular biology. These have far reaching applications as nutritional, cosmetic, pharmaceutical and industrial intermediates. The company has developed over 150 formulations both in therapeutics as well as in nutrition at its three manufacturing facilities offering products like beta carotene, lycopene, and lutein. It is coming up with an INR-400 million DHA docasa hexaenoic acid (DHA) facility in Tiruchendur to be commissioned in fiscal 2008.
The present focus includes work on pharmaceuticals like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-pesticides, bio-monitors and diagnostics, bioremediation and aquaculture. The company has symbiotic and collaborative relationship through joint development programs with institutions of advanced research in India like the National Facility for Marine Cyanobacteria and several others. The company has promoted Samudra Biopharma, which produces betacarotene, lutein, lycopene and other trace carotenoids from marine algae and CellGen Biologicals, a wholly-owned subsidiary of the company, is set up to produce the essential fatty acid DHA. The company entered into a memorandum of understanding with Christian Medical College, Vellore for undertaking joint research in management of various diseases prevalent in the Indian sub-continent.
The registered office is located at No.55, Third East Street, Kamaraj Nagar, Tiruvanmiyur, Chennai-600041.
Financials
ABL Biotechnologies registered a decline in net profit of Rs 6.43 million for the quarter ended September 2007 from a profit of Rs 7.01 million for the quarter ended September 2006.
Net sales rose 11.01% to Rs 59.68 million for the quarter ended September 2007 from Rs 53.76 million for the quarter ended September 2006.
Total income was Rs 60.52 million for the quarter ended September 2007.
The earnings per share (EPS) of the company stood at Rs 1.57 for the quarter ended September 2007.
Recent Developments
17-SEP-07
ABL Biotechnologies is coming up with a Rs 400 million DHA (Docasa Hexaenoic Acid) facility in Tiruchendur. This facility, the first of its kind in the country, will be commissioned in fiscal 2008. The facility will help the company produce DHA at lower cost and thereby enhance its productivity. The company plans to sell DHA, an omega-3 fatty acid, in the form of capsules and fortified foods by 2009.
21-JUL-07
ABL Biotechnologies announced that the company entered into a memorandum of understanding (MoU) with Christian Medical College (CMC), Vellore for undertaking joint research in several areas in management of various diseases prevalent in Indian sub-continent.